HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 55.3%

Neg 0% Neu 0% Pos 55.3%

HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $118 to $120.